Global Cellular and Gene Therapy CDMO Market Growth (Status and Outlook) 2023-2029

Global Cellular and Gene Therapy CDMO Market Growth (Status and Outlook) 2023-2029

LPI (LP Information)' newest research report, the “Cellular and Gene Therapy CDMO Industry Forecast” looks at past sales and reviews total world Cellular and Gene Therapy CDMO sales in 2022, providing a comprehensive analysis by region and market sector of projected Cellular and Gene Therapy CDMO sales for 2023 through 2029. With Cellular and Gene Therapy CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cellular and Gene Therapy CDMO industry.

This Insight Report provides a comprehensive analysis of the global Cellular and Gene Therapy CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cellular and Gene Therapy CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cellular and Gene Therapy CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cellular and Gene Therapy CDMO and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cellular and Gene Therapy CDMO.

The global Cellular and Gene Therapy CDMO market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Cellular and Gene Therapy CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Cellular and Gene Therapy CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Cellular and Gene Therapy CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Cellular and Gene Therapy CDMO players cover Catalent, Lonza, Charles River, The Discovery Labs, BIOCENTRIQ, FUJIFILM Diosynth Biotechnologies, Exothera, WuXi AppTec and Pharmaron, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Cellular and Gene Therapy CDMO market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Cell Therapy
Viral Vectors
Plasmid

Segmentation by application
Commercial
Academic Research
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Catalent
Lonza
Charles River
The Discovery Labs
BIOCENTRIQ
FUJIFILM Diosynth Biotechnologies
Exothera
WuXi AppTec
Pharmaron
OBiO
Cell Therapies
AGC Biologics
Cytiva
Helixmith
ThermoGenesis
Anemocyte
Thermo Fisher Scientific
CBM
Bio Elpida
Genezen
CCRM
RoslinCT
GenScript ProBio
Oxford BioMedica
Porton Pharma Solutions

Please note: The report will take approximately 2 business days to prepare and deliver.